



Published in final edited form as:

Neuroscience. 2015 July 23; 299: 1–17. doi:10.1016/j.neuroscience.2015.04.057.

## ALTERED EXPRESSION OF NEUROPLASTICITY-RELATED GENES IN THE BRAIN OF DEPRESSED SUICIDES

B. FUCHSOVA<sup>a,\*</sup>, A. ALVAREZ JULIÁ<sup>a</sup>, H. S. RIZAVI<sup>b</sup>, A. C. FRASCH<sup>a</sup>, and G. N. PANDEY<sup>b</sup>

<sup>a</sup>Instituto de Investigaciones Biotecnológicas, CONICET-UNSAM, 1650 San Martin, Argentina

<sup>b</sup>Department of Psychiatry, University of Illinois at Chicago, Chicago, IL 60612, USA

### Abstract

**Background**—Expression of the neuronal membrane glycoprotein M6a (GPM6A), the proteolipid protein (PLP/DM20) family member, is downregulated in the hippocampus of chronically stressed animals. Its neuroplastic function involves a role in neurite formation, filopodium outgrowth and synaptogenesis through an unknown mechanism. Disruptions in neuroplasticity mechanisms have been shown to play a significant part in the etiology of depression. Thus, the current investigation examined whether GPM6A expression is also altered in human depressed brain.

**Methods**—Expression levels and coexpression patterns of *GPM6A*, *GPM6B*, and *PLP1* (two other members of PLP/DM20 family) as well as of the neuroplasticity-related genes identified to associate with GPM6A were determined using quantitative polymerase chain reaction (qPCR) in postmortem samples from the hippocampus ( $n=18$ ) and the prefrontal cortex (PFC) ( $n=25$ ) of depressed suicide victims and compared with control subjects (hippocampus  $n=18$ ; PFC  $n=25$ ). Neuroplasticity-related proteins that form complexes with GPM6A were identified by coimmunoprecipitation technique followed by mass spectrometry.

**Results**—Results indicated transcriptional downregulation of *GPM6A* and *GPM6B* in the hippocampus of depressed suicides. The expression level of calcium/calmodulin-dependent protein kinase II alpha (CAMK2A) and coronin1A (CORO1A) was also significantly decreased. Subsequent analysis of coexpression patterns demonstrated coordinated gene expression in the hippocampus and in the PFC indicating that the function of these genes might be coregulated in the human brain. However, in the brain of depressed suicides this coordinated response was disrupted.

© 2015 Published by Elsevier Ltd.

\*Corresponding author. Address: Instituto de Investigaciones Biotecnológicas, Universidad Nacional de General San Martín, Av. 25 de Mayo y Francia, Edificio IIB, 1650 San Martín, Buenos Aires, Argentina. Tel: +54-11-4006-1500x2127; fax: +54-11-4006-1500x2125. beata@iibintech.com.ar (B. Fuchsova).

### CONFLICT OF INTEREST

The authors report no biomedical financial interests or potential conflicts of interest. Dr. Pandey reports grants from USA: National Institutes of Health, during the conduct of the study.

### AUTHOR CONTRIBUTIONS

Conceived and designed the experiments: BF. Performed the experiments: BF AAJ HR. Analyzed the data: BF AAJ. Interpretation of data: BF ACF GNP. Wrote the paper: BF.

**Conclusions**—Disruption of coordinated gene expression as well as abnormalities in *GPM6A* and *GPM6B* expression and expression of the components of GPM6A complexes were detected in the brain of depressed suicides.

### Keywords

postmortem; mRNA expression; coexpression analysis; glycoprotein M6a; qPCR

---

## INTRODUCTION

Neuroplasticity is the mechanism by which information is stored and maintained within individual synapses, neurons, and neuronal circuits to guide organism behavior. Several lines of evidence demonstrate impairment of neuroplasticity in depression (Pittenger and Duman, 2008; Christoffel et al., 2011). For example, in patients with different types of depression, the hippocampus and the prefrontal cortex (PFC) are both reduced in size and activity, and alterations in synaptic and morphological plasticity have been reported (Rajkowska et al., 1999; Stockmeier et al., 2004; Drevets et al., 2008; Pittenger and Duman, 2008; Kang et al., 2012). The histopathological correlates include reductions in synapses or synaptic proteins, reductions in neuronal size, and in neuropil (Drevets et al., 2008). Similar alterations have been observed in animal models of chronic stress: reductions in dendritic arborizations and a loss of highly specialized dendritic spines and synapses in regions that appear homologous to the areas where reductions are evident in depressed humans (i.e., PFC, hippocampus) (McKittrick et al., 2000; Radley et al., 2004; Drevets et al., 2008; Pittenger and Duman, 2008). The intracellular mechanisms underlying these alterations and their relevance to human depression are poorly understood.

The neuronal membrane glycoprotein M6a (GPM6A), a member of the myelin proteolipid protein (PLP/DM20) family, has been shown to play a role in stress response in different animal models (Alfonso et al., 2004a,b; Cooper et al., 2009; Monteleone et al., 2014). For example, chronic social and physical stress decreases *Gpm6a* mRNA levels in the hippocampus, and this downregulation is prevented by administration of antidepressants (Alfonso et al., 2004b, 2006). An association of the *GPM6A* gene with a depression subgroup of schizophrenia patients (Boks et al., 2008) as well as a critical role of GPM6A expression levels for cognitive function have been reported recently (Gregor et al., 2014). *Gpm6a* knockout mouse model is viable and shows no gross malformations or behavioral abnormalities (El-Kordi et al., 2013). However, after mild social stress by single housing, these mice displayed a claustrophobia-like phenotype. Interestingly, in humans a 3'UTR variant of *GPM6A* has been linked to claustrophobia in two pedigrees (El-Kordi et al., 2013).

Apart from *Gpm6a*, other members of the family, the closely related *Gpm6b* and *Dm20* (*Plp1* transcript variant), but not *Plp1* itself, have been shown to be downregulated by chronic stress (Fernandez et al., 2010). Remarkably, the myelin proteolipid protein (PLP/DM20) family members, such as GPM6A, GPM6B, and PLP1 transcript variant DM20, but not PLP1 (Fernandez et al., 2010), have been shown to be involved in the processes of neurite outgrowth and filopodium formation (Lagenaur et al., 1992; Mukobata et al., 2002;

Alfonso et al., 2005; Michibata et al., 2008; Zhao et al., 2008; Fuchsova et al., 2009; Brocco et al., 2010; Scorticati et al., 2011). GPM6A, in particular, is also required for filopodium motility and synaptogenesis (Fuchsova et al., 2009; Brocco et al., 2010), and it has been implicated in neuronal differentiation of human stem cells (Michibata et al., 2009) and PC12 cells (Mukobata et al., 2002). When siRNA methodology is used, GPM6A low-expressing neurons display decreased filopodia numbers and a lower density of synaptophysin clusters (Alfonso et al., 2005).

Neurite growth and remodeling, as well as filopodium and spine formation, represent fundamental processes during neuroplasticity. Thus, we hypothesized that alterations in the expression of the stress responsive neuroplasticity-related genes such as the members of the PLP family could suggest that the cellular pathways that involve these genes are sensitive to disease condition. This would result in dysregulation of neuroplasticity mechanisms involved in the etiology of this disease. Therefore, we examined in the present study the expression of PLP family members *GPM6A*, *GPM6B*, and *PLP1* in the hippocampus ( $n=18$ ) and the PFC ( $n=25$ ) of depressed suicides. The mechanisms and signaling pathways that mediate GPM6A neuroplastic effects are still unknown. Thus, we also identified the neuroplasticity-related proteins that form complexes with GPM6A and examined their expression as well.

## EXPERIMENTAL PROCEDURES

### Subjects

The study was performed in PFC (Brodmann area 9) samples from suicide ( $n=25$ ) and matched nonpsychiatric control subjects ( $n=25$ ). Brain tissues from the same cohort have been used previously in various studies published by our group (Dwivedi et al., 2008; Dwivedi et al., 2009, 2010; Pandey et al., 2014). Dissected regions of interest included predominantly cortical gray matter. The white matter was removed as much as possible, but there was still some white matter left. Hippocampi were available for 18 suicide subjects and 18 nonpsychiatric controls. Postmortem brain samples were obtained from the Maryland Brain Collection at the Maryland Psychiatric Research Center, Baltimore. Tissues were collected only after a family member gave informed consent. Brain samples were free of neuropathologic abnormalities or human immunodeficiency virus antibodies. Toxicological data were obtained by an analysis of urine and blood samples. Psychiatric diagnoses in suicide and control subjects were evaluated with the Diagnostic Evaluation After Death (Salzman et al., 1983) and the Structured Clinical Interview for *DSM-IV* (Spitzer et al., 1995). Family members gave permission for clinical records to be obtained from mental health treatment providers in all cases of suicide. Control subjects were verified to be free from mental illnesses using a consensus diagnostic procedure. All procedures were approved by the Institutional Review Board of the University of Illinois at Chicago. Detailed demography of subjects is provided in Table 1.

### RNA isolation and reverse transcription

Total RNA was extracted from 100 mg of tissue using the Trizol<sup>®</sup> (Invitrogen, Carlsbad, California) according to the manufacturer's directions. RNA concentration and purity were

determined by measuring the OD A260/A280 and A260/A230 using NanoDrop<sup>®</sup>ND-1000 (NanoDrop Technologies, Montchanin, Delaware). All samples were free of contaminants with absorbance ratios close to two. RNA quality was assessed using Agilent Bioanalyzer 2100. All samples had 28S/18S ratios >1.2 and RNA integrity number (RIN) above 6.6. First-strand cDNA was synthesized from 1 µg of total RNA using MMLV-reverse transcriptase (Invitrogen) in the presence of random hexamers (2.5 µM) (Invitrogen) according to manufacturer's instructions.

### Oligonucleotide primers

Primer Express 3.0 software (Applied Biosystems, Foster City, CA, USA) was used to design primers for the amplification of human *GPM6A*, *GPM6B*, *PLP1*, *CORO1A*, *GIT1*, *CAMK2A*, *BDNF* and five candidate internal reference genes (*GAPDH*, *YWHAZ*, *CYCL1*, *PPIA*, and *EIF4A2*). Primer sequence, full gene name, accession number, function, and chromosomal localization are listed in Table 2 (reference genes) and Table 3 (target genes).

### Quantitative polymerase chain reaction (qPCR)

To determine mRNA levels, qPCR reactions were performed using SYBR<sup>®</sup>Select Master Mix (Applied Biosystems) according to the manufacturer's instructions. Measurements were done on Stratagene Mx3005P equipped with MxPro software (Stratagene, La Jolla, CA, USA). All reactions were performed in duplicate. No-RT control, no-template control and three different inter-run calibrators were always included for each individual plate and gene assay. After the final cycle of PCR, reactions were subjected to a heat dissociation protocol to verify primer specificity. A single peak corresponding to the melting temperature ( $T_m$ ) of expected qPCR assay product was observed for all pairs of primers assayed (Fig. 1C). Reproducibility of the reverse transcription (RT) reaction and inter-run reproducibility of qPCR was evaluated by measuring twice the expression of *GPM6A* and *PPIA* in eight randomly selected samples as shown in the Fig. 1A (reproducibility of two independent RT reactions) and 1B (reproducibility of two independent qPCR runs) (Fig. 1A, B). Relative expression levels, reported as fold change (FC), were determined by the relative standard curve method as described in the Applied Biosystems Guide to Performing Relative Quantitation of Gene Expression using Real-Time Quantitative PCR. Standard curves were constructed using 10-fold serial dilutions of cDNA derived from all subjects and the linear range and PCR reaction efficiency of each gene assay were determined. All gene assays were found to have  $r^2 = 0.988$  and efficiencies between 90 and 110 percent (Fig. 1C). Raw expression data ( $C_T$  values) were analyzed by qBasePLUS software (Biogazelle, Zwijnaarde, Belgium). Data are normalized to the normalization factor calculated as a geometric mean of the expression of three reference genes and normalized values are used for further statistical analysis (Vandesompele et al., 2002). Outliers were excluded before analysis if the normalized values were greater than two standard deviations from the group mean.

### Determination of reference targets for qPCR data normalization

The algorithm geNorm of qBasePLUS software was used to evaluate expression stability of reference genes used for qPCR data normalization as described (Vandesompele et al., 2002).

Gene stability of five candidates (*EIF4A2*, *YWHAZ*, *GAPDH*, *CYCI*, and *PPIA*) was evaluated. Special attention was paid to selecting genes that belong to different functional classes, which significantly reduces the chance that genes might be coregulated (see the Table 2 for full gene name, accession number, function, chromosomal localization, and primer sequences).

The reference targets *PPIA*, *CYCI*, and *GAPDH* were determined as the most stably expressed genes and the optimum number of three reference candidates was found adequate for the optimal normalization of data in our experimental setting (Fig. 2A–C). Fig. 2D shows that control and suicide samples did not differ with respect to *GAPDH*, *CYCI* and *PPIA* mRNA expression levels. The geometric mean of *GAPDH*, *CYCI*, and *PPIA* was further used for normalization in all relative quantitation assays.

### Immunoprecipitation (IP) and mass spectrometry

Hippocampal tissue from a two-month-old female Wistar rat was dissected and collected in lysis buffer (150 mM NaCl, 50 mM Tris/HCl, 1% deoxycholate sodium salt, 0.1% SDS, pH 8) supplemented with protease inhibitor cocktail (Sigma–Aldrich, St Louis, MO, USA) to prepare the protein extract. The precleared protein extract was then incubated with the polyclonal antibody against the C-terminus of rat GPM6A developed in our laboratory (Fernandez and Frasch, unpublished results) covalently bound to Protein A–Sepharose via dimethyl pimelimidate (Sigma–Aldrich) as described (Harlow and Lane, 1988). As a control, non-immune rabbit serum was used. Alkylation of the samples to block cysteine residues was performed by treatment with iodoacetamide (Sigma–Aldrich) at the final concentration of 20 mM. The immunoprecipitates were analyzed by SDS–PAGE followed either by Western blotting or by mass spectrometry. In the second case, polyacrylamide gels were silver stained by the mass spectrometry compatible staining method. Only specifically bound proteins not detectable in control immunoprecipitates were excised from the gel, subjected to tryptic digest and analyzed by mass spectrometry.

### Peptide sequencing

In order to obtain internal peptide sequences, *in-gel* tryptic digestion was performed as described (Hellman et al., 1995), peptides were separated using reversed-phase HPLC in a 150-mm × 1-mm Kromasil C<sub>18</sub> column, and sequenced in an Applied Biosystems, model 494 A Procise Automatic Sequencer (Applied Biosystems), run according to the manufacturer's instructions.

### Matrix-assisted laser desorption-ionization time-of-flight-MS (MALDI-TOF-MS)

MALDI-TOF-MS was performed on a Bruker Autoflex, operated for analysis of intact proteins in linear mode and externally calibrated with trypsinogen (23.98 kDa), protein A (44.61 kDa) and BSA (66.43 kDa). Prior to analysis, the sample was desalted by micro-reversed-phase chromatography. The crystals were prepared by the double-layer technique using sinapinic acid as matrix. For peptide mass fingerprinting, tryptic digests were analyzed using a dried droplet preparation with alfa-cyano 4-hydroxy cinnamic acid as matrix. Calibration was done internally, with autolytic peptides from the porcine trypsin used for digestion. The manufacturer's instructions were followed, and the resulting peptide mass

lists were used to scan the latest NCBI nr sequence database for protein identity using the search engine ProFound.

### Plasmid transfection, SDS–PAGE, and Western blot

COS7 cells cultured in Dulbecco's modified Eagle's medium with 10% (v/v) fetal bovine serum, penicillin, and streptomycin were transfected with plasmids encoding a green fluorescent protein (GFP) or a fusion protein GPM6A-GFP using Lipofectamine<sup>®</sup>2000 (Invitrogen) following the manufacturer's instructions. Twenty-four hours later, cells were lysed and the protein samples for SDS–PAGE were prepared as described (Fuchsova et al., 2009). The protein samples were separated on 10% SDS–PAGE gels and transferred to a nitro-cellulose membrane by electroblotting. The membranes were blocked in Tris-buffered saline containing 5% nonfat dried milk and incubated with the rabbit anti-GFP polyclonal serum (1/750) (Invitrogen) or with the polyclonal anti-GPM6A antibody (1/400) developed in our laboratory. Antigen–antibody complexes were detected using an anti-rabbit horseradish peroxidase-linked secondary antibody (1/10,000) (Dako, Glostrup, Denmark) according to standard Enhanced Chemiluminescence protocol using SuperSignal West Pico/Femto chemiluminescent substrate (Pierce, Rockford, IL, USA).

### Statistical analysis

Data were analyzed by analysis of covariance (ANCOVA) independently for each brain region and gene of interest to compare control subjects and depressed suicide victims adjusting the effects of age, postmortem interval (PMI), and brain pH. For multiple comparisons, Bonferroni correction to maintain alpha at 0.05 was used to adjust the type I error rates. Results are reported as individual values and group mean±SD. For correlation analysis of mRNA expression levels, pairwise Pearson correlation coefficients along with its 95% confidence intervals, and *p* value (two-tailed) were calculated on normalized mRNA expression levels. Pearson correlation values *p*<0.05 were considered significant. Chi-square analyses were conducted to determine whether the frequency of significant correlations differed between groups. Statistical analysis and graphs were done with GraphPad Prism software.

## RESULTS

### Demographic characteristics

Detailed demographic characteristics of suicide and control subjects are provided in Table 1. The age range of suicide subjects and controls was between 22 and 74 years, and the PMI was between 5 and 31 h. There were no significant differences between suicide subjects and their matched controls in age (*p*=0.8292, unpaired *t*-test, two-tailed) or PMI (*p*=0.2132, unpaired *t*-test, two-tailed). The mean brain pH±SD in controls was 7.01±0.15 and in suicides was 7.00±0.14, which was not significantly different (*p*=0.8436, unpaired *t*-test, two-tailed). The mean RIN±SD in the PFC was 7.21±0.56 in the control group and 7.23±0.61 in the depressed group. In the hippocampus, the mean RIN±SD was 7.16±0.72 in the control group and 7.45±0.83 in the depressed group. There was no difference in RIN values between controls and depressed suicide subjects in both the PCF and the hippocampus (*p*=0.7 and *p*=0.37; respectively, unpaired *t*-test, two-tailed).



### **GPM6A expression is downregulated in the hippocampus of depressed suicides**

To determine whether the altered expression of *GPM6A* is associated with the pathophysiology of human depression, its mRNA level was measured in the entire cohort by qPCR. Stress responsiveness and cellular function is conserved among the members of the PLP/DM20 family (Fernandez et al., 2010). Thus, we also examined *GPM6B* and *PLP1* expression.

Fig. 3A, B show mRNA levels of *GPM6A*, *GPM6B*, and *PLP1* in the PFC (Fig. 3A) and in the hippocampus (Fig. 3B) of depressed suicides and matched non-psychiatric controls. In the PFC, no significant differences were observed between the control and depressed groups for any of the members. On the other hand, *F*-test of ANCOVA showed that in the hippocampus, the mean *GPM6A* mRNA level was significantly decreased in the depressed group ( $F=14.55$ ,  $p=0.0002$ ,  $FC=0.82$ ). Closely related *GPM6B* also demonstrated a significant decrease ( $F=12.98$ ,  $p=0.0005$ ,  $FC=0.80$ ) and no changes were observed for *PLP1*.

As a control, we evaluated the expression of *BDNF* because the decreased *BDNF* mRNA level in postmortem PFC and hippocampus of depressed suicides has been reported frequently in the past (Dwivedi et al., 2003; Duman and Monteggia, 2006). As expected, *BDNF* mRNA levels were significantly decreased in the depressed subjects compared with controls in both the PCF and the hippocampus ( $F=16.39$ ,  $p=0.0001$ ,  $FC=0.79$ , and  $F=12.65$ ,  $p=0.0006$ ,  $FC=0.64$ ; respectively) (Fig. 2E). The age, PMI and brain pH had no significant effects on mRNA expressions of *GPM6A*, *GPM6B*, and *PLP1*.

### **Coronin1A (CORO1A), calcium/calmodulin-dependent protein kinase II alpha (CAMK2A), and GIT1 co-immunoprecipitate with the stress-responsive glycoprotein GPM6A**

To identify the underlying molecular mechanism through which *GPM6A* affects neuronal remodeling and plasticity, we searched for proteins that associate with *GPM6A*. For this purpose, first, the polyclonal antibody against the C-terminus of *GPM6A* was developed and purified. Western blot in the Fig. 4A shows that the anti-*GPM6A* antibody recognizes the endogenous *GPM6A* (~35 kDa) in the lysate from rat hippocampus (Hipp; 1st lane) and the exogenous *GPM6A* overexpressed as a GFP-fusion protein (~62 kDa) in non-neuronal cell line COS7 (3rd lane). No signal was detected when COS7 were transfected with GFP alone (2nd lane). The polyclonal anti-GFP antibody recognizes both *GPM6A*-GFP and GFP when overexpressed in COS7 cells (4th–5th lane; respectively).

Subsequently, immunoprecipitation of the endogenous *GPM6A* from the rat hippocampal lysate was performed using the anti-*GPM6A* antibody covalently coupled to protein A-Sepharose (Fig. 4B, lane 2). As a control, non-immune rabbit serum covalently coupled to protein A-Sepharose was used (Fig. 4B, lane 1). Using mass spectrometry, *GPM6A* protein was correctly identified in the immunoprecipitate. In addition, among other proteins, cytoskeleton- and neuroplasticity-related proteins, such as *GIT1*, *CORO1A*, and *CAMK2A*, were identified to coimmunoprecipitate with *GPM6A* (Fig. 4B, arrows; see the table in the Fig. 4C for the complete list of identified proteins).

## Altered expression of *CORO1A*, *GIT1*, and *CAMK2A* in the postmortem brain of depressed suicides

Next, we evaluated whether the expression of the genes encoding the proteins identified to form complexes with *GPM6A* (namely *GIT1*, *CORO1A*, and *CAMK2A*) is altered in the postmortem brain of depressed suicide subjects. Fig. 5 shows mRNA levels of *CORO1A*, *GIT1*, and *CAMK2A* in the PFC (Fig. 5A) and in the hippocampus (Fig. 5B) of depressed suicides and matched non-psychiatric controls.

For *CORO1A* and *CAMK2A*, our ANCOVA analysis showed significant differences between the depressed and the control group in the hippocampus ( $F=25.45$ ,  $p<0.0001$ ,  $FC=0.73$ , and  $F=18.47$ ,  $p<0.0001$ ,  $FC=0.70$ ; respectively). We did not observe any significant changes for *CORO1A* and *CAMK2A* in the PFC. Expression of *GIT1* mRNA did not differ in either of the tissues. The age, PMI and brain pH had no significant effects on mRNA expressions of *CORO1A*, *CAMK2A*, and *GIT1*.

### Coordinated expression

To determine whether interrelationships existed among the *GPM6A* levels and *GIT1*, *CORO1A*, and *CAMK2A* expression, and among the expression of the two other members of PLP/DM20 family—*GPM6B* and *PLP1*—cross-correlation analyses were conducted independently for each brain region among the depressed suicides and in the control group. This type of analysis allows us to detect coordinated changes in gene expression if the pathway is affected by disease. Pearson correlation coefficients and  $p$  values were calculated for all genes on normalized mRNA expression levels for the control group and the depression group separately in the PFC and in the hippocampus.

Fig. 6A shows correlation matrices where statistically significant Pearson correlation  $p$  values are indicated by asterisks. In both the hippocampus and the PFC of control individuals, significant interrelationships were frequent. Specifically, in the control PFC, 9 of 15 possible correlations were statistically significant. Within the hippocampus of control individuals, 7 of 15 correlations were statistically significant. The correlations evident in controls differed from the correlations that were significant in the suicide brain. The reduction of correlations was observed in the PFC, where only five correlations were significant, as well as in the hippocampus, where the number of significant correlations declined to one. In the hippocampus, the difference in the frequency of significant correlations between the depressed suicide group and the control group was statistically significant (chi-square=6.136,  $p=0.0132$ ).

Fig. 6B depicts the network of the gene coexpression patterns in the control and depressed groups to illustrate our findings. In both tissues of the control group, correlated genes formed an extensive inter-connected network, suggesting they function in common signaling cascades. In the depressed group, this coordinated gene expression is considerably altered in the PFC and notably, it completely disappears in the hippocampus, where the only correlation detected was between *GPM6A* and *CORO1A*.



### Effect of psychotropic drugs and gender

Since several subjects in the depressed suicide group were on antidepressant medication at the time of death and/or suffered from comorbid substance abuse, we examined if the presence of psychotropic drugs had any influence on the mRNA expression of studied genes. In the depressed suicide group, there were 14 subjects who were on different types of antidepressants and seven subjects who were free of any psychotropic medication. When we compared the mRNA expression of studied genes, we did not find any significant differences between these two groups, suggesting that the presence of antidepressants did not have a significant influence on the expression of *GPM6A*, *GPM6B*, *CORO1A*, *PLP1*, *GIT1*, and *CAMK2A*. Thus, the differences in the *GPM6A*, *GPM6B*, *CORO1A*, and *CAMK2A* expression in the hippocampus between the depressed suicide group and normal controls do not appear to be related to the presence of psychotropic drugs.

To assess the effect of gender on gene expression we analyzed the data by a two-way ANOVA independently for each brain region with diagnosis and gender as categorical independent variables adjusting the effects of age, PMI, and brain pH. The only gene expression where a significant gender by diagnosis interaction was revealed was *GPM6B* expression in the PFC ( $F=8.31$ ,  $p=0.0062$ ). No effect on *GPM6B* expression was detected in the hippocampus. To further investigate this gender by diagnosis effect on *GPM6B* expression in PFC, we conducted ANCOVA analysis on males and females separately. A significant decrease in the *GPM6B* expression was observed in depressed male subjects ( $F=10.63$ ,  $p=0.0016$ ) but not in female subjects.

## DISCUSSION

In our previous studies, we showed that chronic stress, a factor with a clear role in the etiology of depression, reduces the hippocampal mRNA levels of PLP/DM20 family members in animal models of chronic psychosocial or physical stress (Alfonso et al., 2004b, 2006). In the present work, we demonstrate that, *GPM6A* mRNA levels are significantly reduced in the hippocampus of depressed suicides. Moreover, the closely related *GPM6B*, but not *PLP1*, is downregulated.

Previous studies by *in situ* hybridization have indicated that PLP1, the major component of myelin sheets, is expressed in glial cells but not neurons, *GPM6B* is expressed in glial cells and neurons, whereas *GPM6A* is restricted to the latter (Yan et al., 1996). Extensive evidence supports the dysfunction of oligodendrocytes in major depression. Among other alterations, reduced oligodendrocyte numbers in amygdala and PFC have been observed and downregulation of oligodendrocyte-related gene transcripts has been reported in the brain of depressed subjects in regions including the amygdala and PFC (Edgar and Sibille, 2012). In addition, PLP1 itself was shown to be downregulated in the temporal cortex of depressed subjects (Aston et al., 2005). Taking into account the overlap of the functions of PLP1 and *GPM6B* in developmental myelination (Jahn et al., 2009; Werner et al., 2013), we could hypothesize that reduced *GPM6B* expression might participate in oligodendrocyte dysfunction associated with depression even though the PLP1 expression was not altered in our study.

Chronic stress induces profound behavioral changes in humans and rodents, manifested as depressive-like symptoms, a hyperanxious state, and learning/memory deficits, paralleled by structural damage and impaired synaptic plasticity, mainly in the hippocampus and PFC (Pittenger and Duman, 2008). Stress-induced functional deficits have been shown to propagate from a hippocampus-dependent task to a PFC-dependent task (Cerqueira et al., 2007). We could speculate that region-specific downregulation of PLP family member genes in the hippocampus may reflect a region's vulnerability to the diseases and involvement of their gene products in underlying disruptions of hippocampus-dependent tasks (Pittenger and Duman, 2008). For example, GPM6A potential involvement in the hippocampus-dependent memory would be in agreement with the impaired long-term memory performance of M6 (GPM6A ortholog in fly)-deficient and overexpressing flies (Gregor et al., 2014) and identification of *de novo* duplication of *GPM6A* in a patient with learning disability. In fly, M6 shows particularly strong expression in the fly mushroom body (Zappia et al., 2012), which is important for learning and memory processes in *Drosophila* (McGuire et al., 2001). Another potential mechanism involved in observed region-specific effects could be neurogenesis known to play a critical role in the pathophysiology of depression. Findings by Michibata et al. (2008) suggest that expression level of GPM6A is directly or indirectly associated with the differentiation of neurons derived from undifferentiated embryonic stem cells. However, the involvement of PLP1 family members in adult neurogenesis has not been explored at the moment.

GPM6A functions in processes of neuronal remodeling and plasticity, such as neurite outgrowth, filopodium formation, and synaptogenesis (Alfonso et al., 2005; Fuchsova et al., 2009; Brocco et al., 2010; Scorticati et al., 2011). Its overexpression induces neurite formation and increases filopodia density in hippocampal neurons. Similarly, GPM6B and DM20, but not PLP1, induce filopodium formation in primary hippocampal neurons (Fernandez et al., 2010).

Dendrites, dendritic filopodia (precursors to spine synapses), and spines are crucial components for synaptic function and plasticity. Changes in their density or morphological features can result in significant alterations in the connectivity of neural systems (Segal, 2005; Chen et al., 2007) and would be expected to result in changes in the neurobehavioral functions subserved by those systems. We suppose that the reduction in *GPM6A* expression in the depressed suicide brain might be related to the morphological alterations found in the brain of depressed humans.

Synapses between neurons can change functionally and structurally in response to activity in a process known as synaptic plasticity. Apart from alterations in structural plasticity, disruptions in functional synaptic plasticity have also been reported in depression. Among the molecules implicated in synaptic plasticity, CAMK2A has been established as an enzyme of central importance (Lisman et al., 2002; Zhang et al., 2008; Lucchesi et al., 2011). Previous studies have suggested the involvement of CAMK2 in the pathophysiology of psychiatric conditions, including bipolar disorder (Xing et al., 2002), Alzheimer disease (Amada et al., 2005), schizophrenia, and depression (Novak et al., 2006) as well as in the mechanism of action of antidepressants (Lisman et al., 2002; Celano et al., 2003; Tiraboschi et al., 2004; Barbiero et al., 2007; Lucchesi et al., 2011). CAMK2A is expressed postnatally

during brain maturation and stabilizes dendritic arbor structure (Wu and Cline, 1998). It is the most abundant protein in the postsynaptic density (PSD) (Cheng et al., 2006), where the activated CAMK2A phosphorylates AMPA receptors and other PSD proteins, which likely contributes to enhancement of synaptic strength (Lisman et al., 2002). In our study, CAMK2A has been identified as one of the proteins that form complexes with GPM6A. Moreover, we observed significantly lower *CAMK2A* expression in the hippocampus of depressed suicides. We hypothesize that the observed downregulation of CAMK2A could decrease the potential for synaptic plasticity in agreement with reductions in neuroplasticity in depression. Other findings show that synaptic CAMK2A targeting depends on an intact F-actin cytoskeleton (Jalan-Sakrikar et al., 2012). Indeed, actin is essential for functional and structural plasticity and specific mechanisms of cytoskeleton regulation are integral to the processes of neuronal remodeling (Hotulainen and Hoogenraad, 2010; Svitkina et al., 2010). These pathways mainly converge on the Rho family of small GTPases such as RhoA, Rac1, or Cdc42. In line with these observations, the other two proteins that we identified as components of GPM6A complexes are *CORO1A* and *GIT1*. *CORO1A* belongs to a family of WD40 domain-containing proteins that control diverse aspects of F-actin polymerization and branching cycle. It binds filamentous actin, Arp2/3 complex (Chan et al., 2011) and regulates the plasma membrane localization and activation of Rac1 (Castro-Castro et al., 2011). On the other hand, *GIT1* functions as an integrator of signaling pathways controlling vesicle trafficking, adhesion, and cytoskeletal organization. It also regulates spine morphogenesis and synapse formation by targeting actin regulators and locally modulating Rac activity at synapses (Zhang et al., 2003, 2005; Webb et al., 2007). Here, we observed that *CORO1A*, but not *GIT1* expression is downregulated in the hippocampus in the depressed group. Our findings are consistent with the previously described role of structural plasticity in depression (Christoffel et al., 2011). The pathway analyses of gene ontology groups commonly identify structural plasticity- and cytoskeleton-related signaling pathways as being highly modulated by stress and depression-like behavioral paradigms (Piubelli et al., 2011; Andrus et al., 2012). Furthermore, genetic association studies among individuals with lifetime depression have shown that a pathway consisting of genes that regulate cytoskeletal dynamics significantly associates with anhedonic depression (van Veen et al., 2012).

Gene products that function together in common signaling cascades or protein complexes are expected to show greater similarities in their expression patterns than random sets of gene products (Vidal et al., 2011). Indeed, in the present study we observe significant correlations among the expression levels of *GPM6A*, *GPM6B*, *CORO1A*, *GIT1*, and *CAMK2A*, but not *PLP1* in the hippocampus of control subjects. Positive significant correlations are also observed among *GPM6B*, *CORO1A*, *GIT1*, and *CAMK2A* in the PFC. Here, in addition, negative correlations among *GPM6A*, *CORO1A*, *GIT1*, *CAMK2A*, and *PLP1* are detected. These observations support the fact that these gene products might be co-regulated in the hippocampus and PFC of humans. And although further studies are needed to define detailed mechanisms of interactions of GPM6A with these proteins and will be described elsewhere (B Fuchsova and AC Frasch, unpublished results), we suggest that the neuroplastic function of GPM6A in filopodia and neurite outgrowth could be mediated by signaling pathways that involve *GIT1*, *CORO1A*, and/or *CAMK2A*.

Notably, we observed that the coordinated gene expression is disrupted or reorganized in depressed suicides. In the hippocampus, the only significant correlation detected is between *GPM6A* and *CORO1A* and, in the PFC considerable alterations compared to the control group are observed. Various studies have applied gene coexpression network analysis to associate coexpression modules with psychiatric diseases, providing important insights into the pathways disbalanced in the disease (Merali et al., 2004; Poulter et al., 2010; Zhurov et al., 2012; Gaiteri et al., 2014). Our findings are in agreement with observations that pathological mechanisms leading to depression may affect the coordination of gene expression in the brain (Merali et al., 2004; Gaiteri et al., 2010, 2014; Poulter et al., 2010; Zhurov et al., 2012). This may reflect dysregulation of gene expression and loss of coordinated transcriptional response, although observed changes may result from other regulatory processes such as altered mRNA stability or microRNA actions.

Depression and stress may lead to the downregulation of our targets genes and their functional consequences through different mechanisms. Epigenetic mechanisms could be a possible explanation since *GPM6A* has been identified as a novel target for epigenetic regulation during prenatal stress through changes in methylation status and in posttranscriptional regulation by microRNAs. *GPM6A* mRNA expression has been shown to be modulated by miR-133b (Monteleone et al., 2014) and by miR-124 (El-Kordi et al., 2013). Interestingly, miR-133b expression is modulated by prenatal stress exposure in rats both in the hippocampus and PFC (Monteleone et al., 2014). Whether miR-133b and/or miR-124 regulate *GPM6A* expression in major depression remains to be established. Since one miRNA can target several mRNAs, dysregulation of one or just a few miRNAs could cause differential expression of a wide network of genes, as observed in complex pathologies such as depression (Dwivedi, 2014). Another possible mechanism could involve posttranscriptional regulation similar to what is observed for *PLP1* transcript in schizophrenia patients (Aberg et al., 2006). It has been shown that *QKI*, an RNA-binding protein previously identified as a new candidate gene for schizophrenia, modulates mRNA levels of human oligodendrocyte-related genes, including *PLP1*, in schizophrenia patients through disturbance in its splicing (Aberg et al., 2006). It would be interesting to evaluate association of *QKI* with depression as well as its involvement in modulation of mRNA stability of other members of the *PLP* family.

Major depressive disorder and other neuropsychiatric disorders are complex diseases implicating a large number of genes. Each of them confers a small and incremental risk that potentially converges in dysregulated biological pathways, cellular functions, local circuit changes, and, eventually scales up to brain region pathophysiology (Belmaker and Agam, 2008). Even if differential expression is low or absent, the genetics of complex disease can lead to alterations in the molecular interactions of cellular pathways. Thus, changes in gene-gene correlation may occur and their collective effect may become clear through the coexpression networks (Gaiteri et al., 2014). In this context, changes in coexpression network structure can help to identify candidate disease genes. For example, Rhinn et al. identified a novel mechanism for the alpha synuclein regulation in the context of Parkinson's disease pathology by using differential coexpression to prioritize disease-related molecular targets. The alpha synuclein variant *aSynL*, containing a long 3'UTR, was

identified as the most differentially coexpressed gene in several Parkinson's disease datasets; however, aSynL was not among the most differentially expressed transcripts between patients and controls (Rhinn et al., 2012) and thus would have likely been overlooked by traditional analysis. From this point of view, we consider the loss of coordinated expression in our study of high interest. It suggests that the cellular pathways that involve studied genes are sensitive to disease condition. As for the mechanistic insight, it is tempting to speculate that as a consequence of their altered coexpression, GPM6A morphogenetic function in neurite outgrowth, filopodium formation and synaptogenesis as well as the synaptic plasticity function of CAMK2A and CORO1A would be affected with consequences for neuronal remodeling and connectivity. This would fit with the observations that dendritic complexity and synapse density are reduced in depression (Drevets et al., 2008).

The conclusions that can be drawn on the basis of the present investigation are subject to several limitations. Among other things, our cohort is confounded by the fact that the samples come from those who committed suicide. Although all individuals that had died by suicide had a history of depression (depressed phase in case of bipolar disorder), it is not necessarily the case that the present findings are generalizable to depression where suicidal intent was not present, nor is it the case that suicide itself was without effect (van Heeringen, 2001). Recent studies by Turecki and others have shown that there may be gene expression patterns that are associated with suicidality (Sequeira et al., 2007, 2009) albeit with some overlap in those associated with major depression. Thus, our findings may be relevant to suicidality and/or depression. Moreover, follow-up studies are necessary to determine the impact on the protein levels of studied genes. Despite these limitations, we consider that the observed alterations in mRNA levels and disturbance in coordinated gene expression of the neuroplasticity-related genes represent an important contribution in relation to the efforts of identifying potential candidates associated with mental illness. The observed changes in the balance between mRNA levels of studied genes might result in significant alterations in the neuronal connectivity between brain regions resulting in pathological behaviors.

In the future, global assessment of changes in gene expression would be of great value to help us to identify key molecular networks associated with depression. For example, high-throughput RNAseq detects both coding and noncoding RNAs, is superior for gene network construction, detects alternative spliced transcripts, detects allele-specific expression and can be used to extract genotype information, e.g. nonsynonymous coding single nucleotide polymorphisms. In this sense, it could allow us to look at the system as a whole thus deepening our understanding of such complex diseases such as depression.

## CONCLUSION

Disruption of coordinated gene expression and abnormalities in mRNA expression of *GPM6A*, *GPM6B* and components of GPM6A protein complexes were detected in the brain of depressed suicides.

## Acknowledgments

This study was supported by grants to GNP (RO1 MH 48153 and RO1 MH 98554) from the National Institute of Mental Health, Rockville, MD. This work was also supported by grants to ACF and to BF from the ANPCyT and by grants to BF from the UNSAM, CONICET, and Fulbright Commission. AAJ is recipient of a doctoral fellowship from CONICET. BF and ACF are researchers from CONICET. The funding sources had no role in study design, acquisition, and interpretation of data or writing of the report. We thank Ulf Hellman from the Ludwig Institute for Cancer Research, Uppsala, Sweden for help with mass spectrometry analysis.

## Abbreviations

<b>ANCOVA</b>	analysis of covariance
<b>CAMK2A</b>	calcium/calmodulin-dependent protein kinase II alpha
<b>CORO1A</b>	coronin1A
<b>FC</b>	fold change
<b>GFP</b>	green fluorescent protein
<b>GPM6A</b>	neuronal membrane glycoprotein M6a
<b>PFC</b>	prefrontal cortex
<b>PLP</b>	proteolipid protein
<b>PMI</b>	postmortem interval
<b>qPCR</b>	quantitative polymerase chain reaction
<b>RT</b>	reverse transcription

## References

- Aberg K, Saetre P, Jareborg N, Jazin E. Human QKI, a potential regulator of mRNA expression of human oligodendrocyte-related genes involved in schizophrenia. *Proc Natl Acad Sci U S A*. 2006; 103:7482–7487. [PubMed: 16641098]
- Alfonso J, Aguero F, Sanchez DO, Flugge G, Fuchs E, Frasch AC, Pollevick GD. Gene expression analysis in the hippocampal formation of tree shrews chronically treated with cortisol. *J Neurosci Res*. 2004a; 78:702–710. [PubMed: 15505804]
- Alfonso J, Fernandez ME, Cooper B, Flugge G, Frasch AC. The stress-regulated protein M6a is a key modulator for neurite outgrowth and filopodium/spine formation. *Proc Natl Acad Sci U S A*. 2005; 102:17196–17201. [PubMed: 16286650]
- Alfonso J, Frick LR, Silberman DM, Palumbo ML, Genaro AM, Frasch AC. Regulation of hippocampal gene expression is conserved in two species subjected to different stressors and antidepressant treatments. *Biol Psychiatry*. 2006; 59:244–251. [PubMed: 16140276]
- Alfonso J, Pollevick GD, Van Der Hart MG, Flugge G, Fuchs E, Frasch AC. Identification of genes regulated by chronic psychosocial stress and antidepressant treatment in the hippocampus. *Eur J Neurosci*. 2004b; 19:659–666. [PubMed: 14984416]
- Amada N, Aihara K, Ravid R, Horie M. Reduction of NR1 and phosphorylated Ca<sup>2+</sup>/calmodulin-dependent protein kinase II levels in Alzheimer's disease. *Neuroreport*. 2005; 16:1809–1813. [PubMed: 16237332]
- Andrus BM, Blizinsky K, Vedell PT, Dennis K, Shukla PK, Schaffer DJ, Radulovic J, Churchill GA, Redei EE. Gene expression patterns in the hippocampus and amygdala of endogenous depression and chronic stress models. *Mol Psychiatry*. 2012; 17:49–61. [PubMed: 21079605]



- Aston C, Jiang L, Sokolov BP. Transcriptional profiling reveals evidence for signaling and oligodendroglial abnormalities in the temporal cortex from patients with major depressive disorder. *Mol Psychiatry*. 2005; 10:309–322. [PubMed: 15303102]
- Barbiero VS, Giambelli R, Musazzi L, Tiraboschi E, Tardito D, Perez J, Drago F, Racagni G, Popoli M. Chronic antidepressants induce redistribution and differential activation of alphaCaM kinase II between presynaptic compartments. *Neuropsychopharmacology*. 2007; 32:2511–2519. [PubMed: 17356571]
- Belmaker RH, Agam G. Major depressive disorder. *N Engl J Med*. 2008; 358:55–68. [PubMed: 18172175]
- Boks MP, Hoogendoorn M, Jungerius BJ, Bakker SC, Sommer IE, Sinke RJ, Ophoff RA, Kahn RS. Do mood symptoms subdivide the schizophrenia phenotype? Association of the GMP6A gene with a depression subgroup. *Am J Med Genet B Neuropsychiatr Genet*. 2008; 147B:707–711. [PubMed: 18163405]
- Brocco MA, Fernandez ME, Frasch AC. Filopodial protrusions induced by glycoprotein M6a exhibit high motility and aids synapse formation. *Eur J Neurosci*. 2010; 31:195–202. [PubMed: 20074218]
- Castro-Castro A, Ojeda V, Barreira M, Sauzeau V, Navarro-Lerida I, Muriel O, Couceiro JR, Pimentel-Muinos FX, Del Pozo MA, Bustelo XR. Coronin 1A promotes a cytoskeletal-based feedback loop that facilitates Rac1 translocation and activation. *EMBO J*. 2011; 30:3913–3927. [PubMed: 21873980]
- Celano E, Tiraboschi E, Consogno E, D'Urso G, Mbakop MP, Gennarelli M, de Bartolomeis A, Racagni G, Popoli M. Selective regulation of presynaptic calcium/calmodulin-dependent protein kinase II by psychotropic drugs. *Biol Psychiatry*. 2003; 53:442–449. [PubMed: 12614997]
- Cerqueira JJ, Mailliet F, Almeida OF, Jay TM, Sousa N. The prefrontal cortex as a key target of the maladaptive response to stress. *J Neurosci*. 2007; 27:2781–2787. [PubMed: 17360899]
- Chan KT, Creed SJ, Bear JE. Unraveling the enigma: progress towards understanding the coronin family of actin regulators. *Trends Cell Biol*. 2011; 21:481–488. [PubMed: 21632254]
- Chen LY, Rex CS, Casale MS, Gall CM, Lynch G. Changes in synaptic morphology accompany actin signaling during LTP. *J Neurosci*. 2007; 27:5363–5372. [PubMed: 17507558]
- Cheng D, Hoogenraad CC, Rush J, Ramm E, Schlager MA, Duong DM, Xu P, Wijayawardana SR, Hanfelt J, Nakagawa T, Sheng M, Peng J. Relative and absolute quantification of postsynaptic density proteome isolated from rat forebrain and cerebellum. *Mol Cell Proteomics*. 2006; 5:1158–1170. [PubMed: 16507876]
- Christoffel DJ, Golden SA, Russo SJ. Structural and synaptic plasticity in stress-related disorders. *Rev Neurosci*. 2011; 22:535–549. [PubMed: 21967517]
- Cooper B, Fuchs E, Flugge G. Expression of the axonal membrane glycoprotein M6a is regulated by chronic stress. *PLoS One*. 2009; 4:e3659. [PubMed: 19180239]
- Drevets WC, Price JL, Furey ML. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. *Brain Struct Funct*. 2008; 213:93–118. [PubMed: 18704495]
- Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. *Biol Psychiatry*. 2006; 59:1116–1127. [PubMed: 16631126]
- Dwivedi Y. Emerging role of microRNAs in major depressive disorder: diagnosis and therapeutic implications. *Dialogues Clin Neurosci*. 2014; 16:43–61. [PubMed: 24733970]
- Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, Pandey GN. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. *Arch Gen Psychiatry*. 2003; 60:804–815. [PubMed: 12912764]
- Dwivedi Y, Rizavi HS, Teppen T, Zhang H, Mondal A, Roberts RC, Conley RR, Pandey GN. Lower phosphoinositide 3-kinase (PI 3-kinase) activity and differential expression levels of selective catalytic and regulatory PI 3-kinase subunit isoforms in prefrontal cortex and hippocampus of suicide subjects. *Neuropsychopharmacology*. 2008; 33:2324–2340. [PubMed: 18075493]
- Dwivedi Y, Rizavi HS, Zhang H, Roberts RC, Conley RR, Pandey GN. Aberrant extracellular signal-regulated kinase (ERK)1/2 signalling in suicide brain: role of ERK kinase 1 (MEK1). *Int J Neuropsychopharmacol*. 2009; 12:1337–1354. [PubMed: 19835659]


- Dwivedi Y, Rizavi HS, Zhang H, Roberts RC, Conley RR, Pandey GN. Modulation in activation and expression of phosphatase and tensin homolog on chromosome ten, Akt1, and 3-phosphoinositide-dependent kinase 1: further evidence demonstrating altered phosphoinositide 3-kinase signaling in postmortem brain of suicide subjects. *Biol Psychiatry*. 2010; 67:1017–1025. [PubMed: 20163786]
- Edgar N, Sibille E. A putative functional role for oligodendrocytes in mood regulation. *Transl Psychiatry*. 2012; 2:e109. [PubMed: 22832953]
- El-Kordi A, Kastner A, Grube S, Klugmann M, Begemann M, Sperling S, Hammerschmidt K, Hammer C, Stepniak B, Patzig J, de Monasterio-Schrader P, Strenzke N, Flugge G, Werner HB, Pawlak R, Nave KA, Ehrenreich H. A single gene defect causing claustrophobia. *Transl Psychiatry*. 2013; 3:e254. [PubMed: 23632458]
- Fernandez ME, Alfonso J, Brocco MA, Frasch AC. Conserved cellular function and stress-mediated regulation among members of the proteolipid protein family. *J Neurosci Res*. 2010; 88:1298–1308. [PubMed: 19937804]
- Fuchsova B, Fernandez ME, Alfonso J, Frasch AC. Cysteine residues in the large extracellular loop (EC2) are essential for the function of the stress-regulated glycoprotein M6a. *J Biol Chem*. 2009; 284:32075–32088. [PubMed: 19737934]
- Gaiteri C, Ding Y, French B, Tseng GC, Sibille E. Beyond modules and hubs: the potential of gene coexpression networks for investigating molecular mechanisms of complex brain disorders. *Genes Brain Behav*. 2014; 13:13–24. [PubMed: 24320616]
- Gaiteri C, Guilloux JP, Lewis DA, Sibille E. Altered gene synchrony suggests a combined hormone-mediated dysregulated state in major depression. *PLoS One*. 2010; 5:e9970. [PubMed: 20376317]
- Gregor A, Kramer JM, van der Voet M, Schanze I, Uebe S, Donders R, Reis A, Schenck A, Zweier C. Altered GPM6A/M6 dosage impairs cognition and causes phenotypes responsive to cholesterol in human and drosophila. *Hum Mutat*. 2014; 35:1495–1505. [PubMed: 25224183]
- Harlow, E.; Lane, D. *Antibodies: A Laboratory Manual*. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1988. Coupling antibodies to protein A beads; p. 521–523.
- Hellman U, Wernstedt C, Gonez J, Heldin CH. Improvement of an “In-Gel” digestion procedure for the micropreparation of internal protein fragments for amino acid sequencing. *Anal Biochem*. 1995; 224:451–455. [PubMed: 7710111]
- Hotulainen P, Hoogenraad CC. Actin in dendritic spines: connecting dynamics to function. *J Cell Biol*. 2010; 189:619–629. [PubMed: 20457765]
- Jahn O, Tenzer S, Werner HB. Myelin proteomics: molecular anatomy of an insulating sheath. *Mol Neurobiol*. 2009; 40:55–72. [PubMed: 19452287]
- Jalan-Sakrikar N, Bartlett RK, Baucum AJ 2nd, Colbran RJ. Substrate-selective and Calcium-independent Activation of CaMKII by alpha-Actinin. *J Biol Chem*. 2012; 287:15275–15283. [PubMed: 22427672]
- Kang HJ, Voleti B, Hajszan T, Rajkowska G, Stockmeier CA, Licznernski P, Lepack A, Majik MS, Jeong LS, Banasr M, Son H, Duman RS. Decreased expression of synapse-related genes and loss of synapses in major depressive disorder. *Nat Med*. 2012; 18:1413–1417. [PubMed: 22885997]
- Lagenaur C, Kunemund V, Fischer G, Fushiki S, Schachner M. Monoclonal M6 antibody interferes with neurite extension of cultured neurons. *J Neurobiol*. 1992; 23:71–88. [PubMed: 1564456]
- Lisman J, Schulman H, Cline H. The molecular basis of CaMKII function in synaptic and behavioural memory. *Nat Rev Neurosci*. 2002; 3:175–190. [PubMed: 11994750]
- Lucchesi W, Mizuno K, Giese KP. Novel insights into CaMKII function and regulation during memory formation. *Brain Res Bull*. 2011; 85:2–8. [PubMed: 21070840]
- McGuire SE, Le PT, Davis RL. The role of Drosophila mushroom body signaling in olfactory memory. *Science*. 2001; 293:1330–1333. [PubMed: 11397912]
- McKittrick CR, Magarinos AM, Blanchard DC, Blanchard RJ, McEwen BS, Sakai RR. Chronic social stress reduces dendritic arbors in CA3 of hippocampus and decreases binding to serotonin transporter sites. *Synapse*. 2000; 36:85–94. [PubMed: 10767055]
- Merali Z, Du L, Hrdina P, Palkovits M, Faludi G, Poulter MO, Anisman H. Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region. *J Neurosci*. 2004; 24:1478–1485. [PubMed: 14960621]

- Michibata H, Okuno T, Konishi N, Kyono K, Wakimoto K, Aoki K, Kondo Y, Takata K, Kitamura Y, Taniguchi T. Human GPM6A is associated with differentiation and neuronal migration of neurons derived from human embryonic stem cells. *Stem Cells Dev.* 2009; 18:629–639. [PubMed: 19298174]
- Michibata H, Okuno T, Konishi N, Wakimoto K, Kyono K, Aoki K, Kondo Y, Takata K, Kitamura Y, Taniguchi T. Inhibition of mouse GPM6A expression leads to decreased differentiation of neurons derived from mouse embryonic stem cells. *Stem Cells Dev.* 2008; 17:641–651. [PubMed: 18522499]
- Monteleone MC, Adrover E, Pallares ME, Antonelli MC, Frasch AC, Brocco MA. Prenatal stress changes the glycoprotein GPM6A gene expression and induces epigenetic changes in rat offspring brain. *Epigenetics.* 2014; 9:152–160. [PubMed: 23959066]
- Mukobata S, Hibino T, Sugiyama A, Urano Y, Inatomi A, Kanai Y, Endo H, Tashiro F. M6a acts as a nerve growth factor-gated Ca(2+) channel in neuronal differentiation. *Biochem Biophys Res Commun.* 2002; 297:722–728. [PubMed: 12359212]
- Novak G, Seeman P, Tallerico T. Increased expression of calcium/calmodulin-dependent protein kinase IIbeta in frontal cortex in schizophrenia and depression. *Synapse.* 2006; 59:61–68. [PubMed: 16247765]
- Pandey GN, Rizavi HS, Ren X, Bhaumik R, Dwivedi Y. Toll-like receptors in the depressed and suicide brain. *J Psychiatr Res.* 2014; 53:62–68. [PubMed: 24565447]
- Pittenger C, Duman RS. Stress, depression, and neuroplasticity: a convergence of mechanisms. *Neuropsychopharmacology.* 2008; 33:88–109. [PubMed: 17851537]
- Piubelli C, Carboni L, Becchi S, Mathe AA, Domenici E. Regulation of cytoskeleton machinery, neurogenesis and energy metabolism pathways in a rat gene-environment model of depression revealed by proteomic analysis. *Neuroscience.* 2011; 176:349–380. [PubMed: 21195137]
- Poulter MO, Du L, Zhurov V, Palkovits M, Faludi G, Merali Z, Anisman H. Altered Organization of GABA(A) Receptor mRNA Expression in the Depressed Suicide Brain. *Front Mol Neurosci.* 2010; 3:3. [PubMed: 20407580]
- Radley JJ, Sisti HM, Hao J, Rocher AB, McCall T, Hof PR, McEwen BS, Morrison JH. Chronic behavioral stress induces apical dendritic reorganization in pyramidal neurons of the medial prefrontal cortex. *Neuroscience.* 2004; 125:1–6. [PubMed: 15051139]
- Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD, Meltzer HY, Overholser JC, Roth BL, Stockmeier CA. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. *Biol Psychiatry.* 1999; 45:1085–1098. [PubMed: 10331101]
- Rhinn H, Qiang L, Yamashita T, Rhee D, Zolin A, Vanti W, Abeliovich A. Alternative alpha-synuclein transcript usage as a convergent mechanism in Parkinson's disease pathology. *Nat Commun.* 2012; 3:1084. [PubMed: 23011138]
- Salzman, S.; Endicott, J.; Clayton, P.; Winokur, G. Diagnostic evaluation after death (DEAD). Rockville, MD: National Institute of Mental Health, Neuroscience Research Branch; 1983.
- Scorticati C, Formoso K, Frasch AC. Neuronal glycoprotein M6a induces filopodia formation via association with cholesterol-rich lipid rafts. *J Neurochem.* 2011
- Segal M. Dendritic spines and long-term plasticity. *Nat Rev Neurosci.* 2005; 6:277–284. [PubMed: 15803159]
- Sequeira A, Klempan T, Canetti L, French-Mullen J, Benkelfat C, Rouleau GA, Turecki G. Patterns of gene expression in the limbic system of suicides with and without major depression. *Mol Psychiatry.* 2007; 12:640–655. [PubMed: 17353912]
- Sequeira A, Mamdani F, Ernst C, Vawter MP, Bunney WE, Lebel V, Rehal S, Klempan T, Gratton A, Benkelfat C, Rouleau GA, Mechawar N, Turecki G. Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression. *PLoS One.* 2009; 4:e6585. [PubMed: 19668376]
- Spitzer, R.; Williams, J.; Gibbon, M.; First, M. Structural clinical interview for DSM-IV (SCID). New York, NY: New York State Psychiatric Institute Biometrics Research; 1995.
- Stockmeier CA, Mahajan GJ, Konick LC, Overholser JC, Jurjus GJ, Meltzer HY, Uylings HB, Friedman L, Rajkowska G. Cellular changes in the postmortem hippocampus in major depression. *Biol Psychiatry.* 2004; 56:640–650. [PubMed: 15522247]

- Svitkina T, Lin WH, Webb DJ, Yasuda R, Wayman GA, Van Aelst L, Soderling SH. Regulation of the postsynaptic cytoskeleton: roles in development, plasticity, and disorders. *J Neurosci*. 2010; 30:14937–14942. [PubMed: 21068295]
- Tiraboschi E, Giambelli R, D'Urso G, Galiotta A, Barbon A, de Bartolomeis A, Gennarelli M, Barlati S, Racagni G, Popoli M. Antidepressants activate CaMKII in neuron cell body by Thr286 phosphorylation. *Neuroreport*. 2004; 15:2393–2396. [PubMed: 15640762]
- van Heeringen C. Suicide, serotonin, and the brain. *Crisis*. 2001; 22:66–70. [PubMed: 11727896]
- van Veen T, Goeman JJ, Monajemi R, Wardenaar KJ, Hartman CA, Snieder H, Nolte IM, Penninx BW, Zitman FG. Different gene sets contribute to different symptom dimensions of depression and anxiety. *Am J Med Genet B Neuropsychiatr Genet*. 2012; 159B:519–528. [PubMed: 22573416]
- Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. *Genome Biol*. 2002; 3:RESEARCH0034. [PubMed: 12184808]
- Vidal M, Cusick ME, Barabasi AL. Interactome networks and human disease. *Cell*. 2011; 144:986–998. [PubMed: 21414488]
- Webb DJ, Zhang H, Majumdar D, Horwitz AF. Alpha5 integrin signaling regulates the formation of spines and synapses in hippocampal neurons. *J Biol Chem*. 2007; 282:6929–6935. [PubMed: 17213186]
- Werner HB, Kramer-Albers EM, Strenzke N, Saher G, Tenzer S, Ohno-Iwashita Y, De Monasterio-Schrader P, Mobius W, Moser T, Griffiths IR, Nave KA. A critical role for the cholesterol-associated proteolipids PLP and M6B in myelination of the central nervous system. *Glia*. 2013; 61:567–586. [PubMed: 23322581]
- Wu GY, Cline HT. Stabilization of dendritic arbor structure in vivo by CaMKII. *Science*. 1998; 279:222–226. [PubMed: 9422694]
- Xing G, Russell S, Hough C, O'Grady J, Zhang L, Yang S, Zhang LX, Post R. Decreased prefrontal CaMKII alpha mRNA in bipolar illness. *Neuroreport*. 2002; 13:501–505. [PubMed: 11930170]
- Yan Y, Narayanan V, Lagenaur C. Expression of members of the proteolipid protein gene family in the developing murine central nervous system. *J Comp Neurol*. 1996; 370:465–478. [PubMed: 8807448]
- Zappia MP, Bernabo G, Billi SC, Frasch AC, Ceriani MF, Brocco MA. A role for the membrane protein M6 in the *Drosophila* visual system. *BMC Neurosci*. 2012; 13:78. [PubMed: 22762289]
- Zhang H, Webb DJ, Asmussen H, Horwitz AF. Synapse formation is regulated by the signaling adaptor GIT1. *J Cell Biol*. 2003; 161:131–142. [PubMed: 12695502]
- Zhang H, Webb DJ, Asmussen H, Niu S, Horwitz AF. A GIT1/PIX/Rac/PAK signaling module regulates spine morphogenesis and synapse formation through MLC. *J Neurosci*. 2005; 25:3379–3388. [PubMed: 15800193]
- Zhang YP, Holbro N, Oertner TG. Optical induction of plasticity at single synapses reveals input-specific accumulation of alphaCaMKII. *Proc Natl Acad Sci U S A*. 2008; 105:12039–12044. [PubMed: 18697934]
- Zhao J, Iida A, Ouchi Y, Satoh S, Watanabe S. M6a is expressed in the murine neural retina and regulates neurite extension. *Mol Vis*. 2008; 14:1623–1630. [PubMed: 18776950]
- Zhurav V, Stead JD, Merali Z, Palkovits M, Faludi G, Schild-Poulter C, Anisman H, Poulter MO. Molecular pathway reconstruction and analysis of disturbed gene expression in depressed individuals who died by suicide. *PLoS One*. 2012; 7:e47581. [PubMed: 23110080]

### Highlights

- *GPM6A* and *GPM6B* are transcriptionally downregulated in the hippocampus of depressed suicides.
- Neuroplasticity-related proteins that form complexes with *GPM6A* were identified.
- mRNA of the components of *GPM6A* complexes is decreased in the depressed group.
- Coexpression pattern analysis demonstrates coordinated gene expression in the brain.
- In the brain of depressed suicides this coordinated response is disrupted.

**Fig. 1.**

(A) Correlation studies to evaluate reproducibility of reverse transcription (RT) reaction. Equal amounts of RNA extracted from eight samples were reverse transcribed in two independent RT reactions (1st RT and 2nd RT) and used as a template for qPCR to measure twice the expression of *GPM6A* and *PPIA*. Both genes show a statistically significant correlation (*GPM6A* Pearson coefficient=0.7702, \**p* value (two-tailed)=0.0254; *PPIA* Pearson coefficient=0.7452, \**p* value (two-tailed)=0.0339). (B) Correlation studies to evaluate inter-run reproducibility qPCR reaction. Two identical replica plates containing eight cDNA samples obtained from 1st RT reaction were prepared and used to measure the expression of *GPM6A* and *PPIA* in two independent runs. Both genes show a statistically significant correlation (*GPM6A* Pearson coefficient=0.9882, \*\*\**p* value (two-tailed)< 0.0001; *PPIA* Pearson coefficient=0.8709, \*\**p* value (two-tailed)=0.0049). (C) Efficiency data for candidate reference genes and target genes.  $C_T$  values obtained from 10-fold serial




dilutions of cDNA were plotted against dilution factors and the reaction efficiency was calculated using qBasePLUS software. RT, reverse transcription;  $C_T$ , threshold cycle;  $RSq$ , r-squared;  $R_n$ , normalized reporter signal;  $dR_n$ , delta  $R_n$  ( $R_n$  minus the baseline);  $T_m$ , melting temperature.

Author Manuscript

Author Manuscript


Author Manuscript

Author Manuscript




**Fig. 2.** Expression stability of five candidate reference genes in human brain samples calculated by geNorm algorithm using qBasePLUS software (Biogazelle). GeNorm analysis was performed on the gene expression data from PFC and hippocampal postmortem samples obtained from all depressed suicide subjects and matched nonpsychiatric controls. (A) Average expression stability values (M) of five candidate genes from the least stable to the most stable in PFC. The gene stability measure M is defined as the average pairwise variation of a particular gene with all other control genes (Vandesompele et al., 2002). Genes with lowest values have the most stable expression (optimal geNorm M = 0.5). In the PFC samples, the geNorm gene stability measurement values M were ranked in the following order (from the least to the most stable): *YWHAZ*, *EIF4A2*, *GAPDH*, *CYC1*, and *PPIA*. (B) Determination of the optimum number of reference genes required for adequate data normalization based on pairwise variation ( $V_n/V_{n+1}$ ) between candidate genes in the PFC (optimal geNorm V < 0.15). Normalization to a single control gene can lead to erroneous

normalization. For this reason, geNorm also calculates the pairwise variation value ( $V_{n/n+1}$ ) that shows the effect of adding further reference genes on the normalization factor. When analyzing  $V_{n/n+1}$ , we observed that the stepwise inclusion of individual reference genes showed a decrease until a minimal value ( $V_{3/4}$ ). The next addition of other reference gene determined an increase of  $V_{4/5}$ , suggesting that there was a decrease of expression stability due to the inclusion of a relatively unstable fifth gene. Thus, the adequate number of reference targets in this experimental situation is three when comparing a normalization factor based on three or four most stable targets. (C) Reference target stability values (M and CV) determined for the combination of the reference targets *GAPDH*, *CYCI*, and *PPIA* in human brain samples from the PFC and hippocampus. To assess that the genes with the lowest M values have indeed the most stable expression, the gene-specific variation of each control gene is determined as the variation coefficient (CV) of the expression levels after normalization. Mean CV values lower than 0.2 are typically observed for stably expressed reference genes in relatively homogenous sample panels. As such, in human postmortem PFC and hippocampal samples, the optimal normalization factor can be calculated as the geometric mean of reference targets *PPIA*, *CYCI*, and *GAPDH*. (D) Expression levels of reference genes *GAPDH*, *PPIA* and *CYCI* in the PFC and in the hippocampus of non-psychiatric controls (Control: PFC  $n=25$  for *PPIA* and *CYCI*,  $n=24$  for *GAPDH*; Hippocampus  $n=18$  for *GAPDH*, *PPIA* and *CYCI*) and depressed (Depressed: PFC  $n=25$  for *GAPDH*, *PPIA* and *CYCI*; Hippocampus  $n=18$  for *GAPDH*, *PPIA* and *CYCI*) suicide subjects. Results are expressed as fold change in mRNA levels. Values are fold change $\pm$ SD. No significant differences between the depressed suicide group and the control group were determined for any of the genes. (E) Expression levels of *BDNF* in the PFC and in the hippocampus of non-psychiatric controls (Control: PFC  $n=25$ , Hippocampus  $n=18$ ) and depressed (Depressed: PFC  $n=24$ , Hippocampus  $n=16$ ) suicide subjects. Results are expressed as fold change in mRNA levels. Values are fold change $\pm$ SD. *BDNF* mRNA levels were significantly decreased in the depressed subjects compared with controls in both the PFC and the hippocampus ( $F=16.39$ ,  $p=0.0001$ , and  $F=12.65$ ,  $p=0.0006$ , respectively). Significant effects are marked by asterisks (Bonferroni corrected significance threshold, after correction: asterisk,  $P<0.05$ ; two asterisks,  $P<0.01$ ).



**Fig. 3.** mRNA levels of *GPM6A*, *GPM6B*, and *PLP1* in PFC (A) and in the hippocampus (B) of non-psychiatric controls (Control: PFC  $n=25$  for *GPM6A*, *GPM6B*, and *PLP1*; Hippocampus  $n=18$  for *GPM6A* and *GPM6B*,  $n=17$  for *PLP1*) and depressed (Depressed: PFC  $n=25$  for *GPM6A* and *GPM6B*,  $n=24$  for *PLP1*; Hippocampus  $n=17$  for *GPM6A* and *PLP1*,  $n=16$  for *GPM6B*) suicide subjects normalized to the geometric mean of the three reference targets (*GAPDH*, *CYC1*, *PPIA*). Results are expressed as fold change in mRNA levels. Values are fold change $\pm$ SD. Significant differences between the depressed suicides and the control group were determined for *GPM6A* ( $F=14.55$ ,  $p=0.0002$ ) and *GPM6B* ( $F=12.98$ ,  $p=0.0005$ ) in the hippocampal tissue. Significant effects are marked by asterisks (Bonferroni corrected significance threshold, after correction: asterisk,  $P<0.05$ ; two asterisks,  $P<0.01$ ).



**Fig. 4.** (A) Polyclonal antibody against C-terminus of GPM6A specifically recognizes endogenous as well as exogenous GPM6A protein. Western blot analysis of lysates from adult rat hippocampus (Hipp) and from non-neuronal cell line COS7 overexpressing exogenous GPM6A as a GFP fusion protein (COS7) shows a protein migrating at ~35 kDa (1st lane) corresponding to endogenous GPM6A and a protein migrating at ~62 kDa (3rd lane) corresponding to exogenous GPM6A overexpressed as a GFP fusion protein (COS7). No additional nonspecific bands were detected. No signal was detected when COS7 cells were transfected with GFP alone (2nd lane). The polyclonal anti-GFP antibody recognizes both GPM6A-GFP as well as GFP when overexpressed in COS7 cells (4th and 5th lane respectively). (B) SDS-PAGE analysis of proteins co-immunoprecipitating with GPM6A. The endogenous GPM6A was immunoprecipitated from adult rat hippocampus using the polyclonal antibody against C-terminal end of GPM6A coupled to protein A-Sepharose (lane 2). As a control nonimmune rabbit serum covalently coupled to protein A-Sepharose was used (lane 1). Coimmunoprecipitating proteins were visualized by silver staining

technique compatible with mass spectrometry. The proteins of interest were excised from the gel, subjected to tryptic digest and analyzed by mass spectrometry. G protein-coupled receptor kinase-interacting protein 1 (GIT1), coronin-1A (CORO1A), and calcium/calmodulin-dependent protein kinase 2 alpha (CAMK2A) were identified among proteins that coimmunoprecipitate with GPM6A (arrows). (C) Complete list of proteins co-immunoprecipitating with GPM6A as identified by mass spectrometry.


Author Manuscript

Author Manuscript


Author Manuscript

Author Manuscript





**Fig. 5.** mRNA levels of *CORO1A*, *GIT1*, and *CAMK2A* in the PFC (A) and in the hippocampus (B) of non-psychiatric controls (Control: PFC  $n=25$  for *CORO1A*, *GIT1*, and *CAMK2A*; Hippocampus  $n=18$  for *CORO1A*, *GIT1*, and *CAMK2A*) and depressed (Depressed: PFC  $n=25$  for *CORO1A*, *GIT1*, and *CAMK2A*; Hippocampus  $n=18$  for *CORO1A* and *GIT1*,  $n=17$  for *CAMK2A*) suicide subjects normalized to the geometric mean of the three reference targets (*GAPDH*, *CYCL1*, *PPIA*). Results are expressed as fold change in mRNA levels. Values are fold change $\pm$ SD. Significant differences between the depressed suicide group and the control group were determined for *CORO1A* and for *CAMK2A* in the hippocampal tissue ( $F=25.45$ ,  $p<0.0001$ , and  $F=18.47$ ,  $p<0.0001$ ; respectively). Significant effects are marked by asterisks (Bonferroni corrected significance threshold, after correction: asterisk,  $P<0.05$ ; two asterisks,  $P<0.01$ ).



**Fig. 6.** Coordinated expression is decreased in the brain of depressed suicides. (A) Correlation analysis of mRNA expression levels in the PFC and in the hippocampus. In the matrix all pairwise Pearson correlation coefficients calculated on normalized mRNA expression levels are shown. Statistically significant Pearson correlation p values (two-tailed) are indicated by asterisks (\* $<0.05$ , \*\* $<0.01$ , \*\*\* $<0.001$ , ns=no significant; dark gray indicates a statistically significant correlation, light gray indicates a non significant correlation). In suicide brain (lower portion of the correlation matrix) significant correlations appear less frequently than in controls (upper portion of the correlation matrix). Decrease in the frequency of significant correlations between controls and depressed suicides is statistically significant in the hippocampus (chi-square=6.136, \* $p=0.013$ ; in PFC chi-square=2.143,  $p=0.1432$ ). (B) Network of the gene coexpression pattern in the PFC and in the hippocampus in control and depressed groups. Gene pairs that show a significant correlation are indicated: a positive

significant correlation (full line); a negative significant correlation (dashed line). Dark circles indicate differentially expressed genes. Differences between control and depressed groups are observed in both tissues.

**Table 1**  
Demographic characteristics of depressed suicide victims and normal control subjects

	Age (years)	Race	Gender	PMI (hours)	Brain pH	Cause of death	Psychotropic drugs (at the time of death)	Psychiatric diagnosis
Normal control subjects <sup>a</sup>								
1	CONTROL 22	Black	Male	19	6.9	GSW	None	Normal
2	CONTROL 42	White	Female	23	7.2	Pneumonia	None	Normal
3	CONTROL 37	Black	Male	5	7.1	ASCVD	None	Normal
4	CONTROL 31	Black	Male	8	7.2	GSW	None	Normal
5	CONTROL 46	Black	Male	9	7.1	Multiple injuries	None	Normal
6	CONTROL 33	White	Male	15	7.0	GSW	None	Normal
7	CONTROL 48	White	Male	26	6.9	ASCVD	None	Normal
8	CONTROL 40	White	Female	7	7.0	ASCVD	None	Normal
9	CONTROL 23	Black	Male	15	6.8	GSW	None	Normal
10	CONTROL 38	Black	Male	16	6.9	Lung Sarcoidosis	None	Normal
11	CONTROL 65	Black	Female	23	6.9	ASCVD	None	Normal
12	CONTROL 35	White	Male	24	6.9	Crush injury to abdomen and chest	None	Normal
13	CONTROL 52	White	Male	30	7.3	ASCVD	None	Normal
14	CONTROL 63	White	Female	30	7.1	Ovarian cancer	None	Normal
15	CONTROL 37	White	Male	24	7.0	ASCVD	None	Normal
16	CONTROL 45	White	Male	22	7.3	ASCVD	None	Normal
17	CONTROL 26	White	Male	12	6.9	Arrhythmia	None	Normal
18	CONTROL 72	White	Female	23	6.9	MVA	None	Normal
19	CONTROL 42	White	Female	23	6.9	Mitral valve prolapse	None	Normal
20	CONTROL 47	White	Male	10	7.0	ASCVD	None	Normal
21	CONTROL 31	White	Male	16	7.2	MVA	None	Normal
22	CONTROL 60	White	Male	15	7.1	Accidental drowning	None	Normal
23	CONTROL 28	White	Male	13	6.8	Electrocution	None	Normal
24	CONTROL 45	White	Female	16	6.9	Cardiac arrhythmia	None	Normal
25	CONTROL 62	White	Male	19	7.0	Cardiac arrest	None	Normal
Depressed suicide victims <sup>b</sup>								
1	SUICIDE 27	White	Male	24	7.0	GSW	None	MDD, Ethanol abuse

	Age (years)	Race	Gender	PMI (hours)	Brain pH	Cause of death	Psychotropic drugs (at the time of death)	Psychiatric diagnosis
2	SUICIDE 44	White	Female	11	7.2	Drug OD	Nortriptyline	MDD, Ethanol abuse
3	SUICIDE 36	White	Female	10	7.1	GSW	None	MDD
4	SUICIDE 24	White	Male	7	7.1	GSW	Ethanol	MDD
5	SUICIDE 43	White	Male	12	7.0	Drug OD	None	MDD, Polysubstance Abuse
6	SUICIDE 53	White	Male	23	6.9	Jump from height	None	MDD
7	SUICIDE 41	White	Female	27	7.1	Drug OD	Amitriptyline, Desipramine, Nortriptyline, Ethanol	MDD, Ethanol abuse
8	SUICIDE 22	Black	Female	16	7.3	Drug OD	None	MDD
9	SUICIDE 46	White	Female	21	6.9	Drug OD	Amitriptyline, Desipramine, Ethanol	MDD
10	SUICIDE 36	White	Female	18	7.2	GSW	None	MDD
11	SUICIDE 38	White	Male	24	7.0	Drug OD, Ethanol intoxication	Ethanol	MDD, Ethanol abuse
12	SUICIDE 46	White	Female	16	6.8	Drug OD	Nortriptyline	MDD, Panic disorder with agoraphobia
13	SUICIDE 23	White	Male	12	7.0	Hanging	Paroxetine	MDD
14	SUICIDE 30	White	Male	17	7.1	Hanging	Venlafaxine	MDD
15	SUICIDE 44	White	Female	30	7.2	Drug OD, Ethanol intoxication	Fluoxetine, Ethanol	MDD, Ethanol abuse, Opioid abuse
16	SUICIDE 74	White	Female	27	7.0	Venlafaxine OD	Venlafaxine, Ethanol	MDD, Ethanol abuse
17	SUICIDE 25	White	Male	14	6.8	Hanging	Ethanol	MDD
18	SUICIDE 23	Black	Male	23	6.9	Hanging	None	MDD
19	SUICIDE 63	White	Male	19	6.9	Drug OD, Ethanol intoxication	Ethanol	MDD
20	SUICIDE 67	White	Male	22	7.0	GSW	Fluoxetine, Venlafaxine	MDD
21	SUICIDE 40	White	Female	20	7.0	Drug OD	Xanax	MDD
22	SUICIDE 53	White	Male	26	7.1	Stabbing	Sertraline	MDD
23	SUICIDE 68	White	Female	26	6.8	GSW	Amitriptyline	Bipolar Disorder
24	SUICIDE 31	White	Female	31	6.8	Hanging	Trazadone, Ethanol	Bipolar Disorder, Bulimia, OCD
25	SUICIDE 51	White	Female	28	6.9	Amitriptyline OD	Amitriptyline, Ethanol	Bipolar Disorder, Ethanol abuse

*Abbreviations:* ASCVD, atherosclerotic cardiovascular disease; CO, carbon monoxide; DKA, diabetic ketoacidosis; GSW, gunshot wound; MDD, major depressive disorder; MVA, motor vehicle accident; OCD, obsessive-compulsive disorder; OD, overdose; PMI, postmortem interval.

<sup>a</sup>Mean±SD age is 42.8±13.58 years; PMI, 17.72±7.00 h; and brain pH 7.01±0.15.

<sup>b</sup>Mean±SD age is 41.92±15.07 years; PMI, 20.16±6.68 h; and brain pH 7.00±0.14.

**Table 2**  
Primer sequences for reference genes selected for evaluation of expression stability

Symbol	Entrez Gene ID	Name	Function	Forward primer	Reverse primer	Location
GAPDH	2597	glyceraldehyde-3-phosphate dehydrogenase	Catalysis of oxidative phosphorylation of glyceraldehyde-3-phosphate in the presence of NAD	GAAAGGTGAAAGGTCCGGAGTC	GAAAGATGGTGTATGGGATTTTC	12p13
PP1A	5478	peptidylprolylisomerase A (cyclophilin A)	Peptidyl-prolyl cis-trans isomerase	GGCAAATGCTGGACCCAAACACA	TGCTGGTCTTTGCCCAITTCCTGGA	7p13
CYC1	1537	cytochrome c-1	Electron transporter	CCAGATAGCCAAAGGATGTGTGC	GACTGACCACTTTGTGCCCGCTTT	8q24.3
EIF4A2	1974	eukaryotic translation initiation factor 4A2	Translation initiation factor	CTCTCCTTCGTGGCATCTATGC	TGGCTGTCTTGGCCAGTACCTGA	3q28
YWHAZ	7534	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide	Signal transduction by binding to phosphoserine-containing proteins	ACCGTTACTTGGCTGAGGTTGC	CCCAGTCTGATAGGATGTGTTGG	8q23.1

Table 3

Primer sequences for target genes

Symbol	Entrez Gene ID	Name	Forward primer	Reverse primer	Location
BDNF	627	Brain-derived neurotrophic factor	CATCCGAGGACAAGGTGGCTTG	GCCGAACTTTCTGGTCCCTCATC	11p13
GPM6A	2823	Glycoprotein M6A	ACCTTGACGCTCTTCTTTTCATTATT	CAATGGTCAAATCAGTGCACAA	4q34
GPM6B	2824	glycoprotein M6B	GAATGTTTCGTTTTTCCTCACCTATGT	GGCACCCGCTGAGAAAACCA	Xp22.2
PLP1	5354	proteolipid protein 1	GGCCAAACATCAAAGCTCATTCTT	AGGTGATGCCCACAAACCTTGT	Xq22
CAMK2A	815	Calcium/calmodulin-dependent protein kinase II alpha	AGCCAAGGATCTGATCAATAAGATG	GGCTTCGGCAGCTGTGA	5q32
GIT1	28,964	G protein-coupled receptor kinase interacting ArfGAP 1	CCGAGAGTTTTGCCACCTTGATC	ACGCTGTCGTAGTCGTGTTGGT	17p11.2
CORO1A	11,151	Coronin, actin binding protein, 1A	CCAAACATCGTCTACCTCTGTGG	CTCACACTTGTTCACCTCCAGG	16p11.2